Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.63 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1512308 | 0.92 | CHRM3 (0.72) | CHRM3MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4055933 | 0.87 | CHRM3 (0.88) | CHRM3 | |
| Tert-Butyl Formate SCHEMBL28052662 | 0.84 | CHRM3 (0.64) | CHRM3MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL20209837 | 0.80 | CYP2D6 (0.62) | CHRM3MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1373046 | 0.80 | CYP2D6 (0.67) | CHRM3MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL22653097 | 0.80 | CHRM3 (0.58) | CHRM3MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL12563565 | 0.79 | CYP2D6 (0.69) | CHRM3MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL28744419 | 0.79 | CYP2D6 (0.73) | CHRM3MEN1KMT2ASMN1; SMN2CYP2D6 | |
| SCHEMBL6630922 | 0.78 | MEN1 (0.61) | CHRM3MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL10145077 | 0.78 | ALDH1A1 (0.60) | CHRM3MEN1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | CHRM3 3452/4885SLC2A1 233/4885MEN1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.